PABLO DE LA
CUEVA DOBAO
Profesor asociado
Hospital Universitario Doctor Peset
Valencia, EspañaPublicacións en colaboración con investigadores/as de Hospital Universitario Doctor Peset (8)
2024
-
Efficacy of Risankizumab in Patients with Suboptimal Response or Failure to Ustekinumab: A Multicenter Retrospective Study in Spain
Dermatologic Therapy, Vol. 2024
-
Real-world Safety and Efficacy of Risankizumab in Psoriatic Patients: A Multicenter, Retrospective, and Not-interventional Study
Actas Dermo-Sifiliograficas
-
Safety of biologic therapy in combination with methotrexate in moderate to severe psoriasis: a cohort study from the BIOBADADERM registry
British Journal of Dermatology, Vol. 190, Núm. 3, pp. 355-363
2023
-
Criteria used to define tumor necrosis factor-alpha inhibitors failure in patients with moderate-to-severe psoriasis: a systematic literature review
Annals of Medicine, Vol. 55, Núm. 1, pp. 1335-1345
-
Effectiveness and safety of tildrakizumab for the treatment of psoriasis in real-world settings at 24 weeks: A retrospective, observational, multicentre study by the Spanish Psoriasis Group
Journal of the European Academy of Dermatology and Venereology, Vol. 37, Núm. 12, pp. 2517-2525
-
Treatment of Severe Atopic Dermatitis With Upadacitinib in Clinical Practice: Short-Term Efficacy and Safety Results
Journal of Investigational Allergology and Clinical Immunology
2022
-
Effectiveness and safety of guselkumab for the treatment of psoriasis in real-world settings at 24 weeks: A retrospective, observational, multicentre study by the Spanish Psoriasis Group
Dermatologic Therapy, Vol. 35, Núm. 2
-
Moderate to Severe Psoriasis in Pediatric and Young Patients: The BIOBADADERM Registry Experience
Actas Dermo-Sifiliograficas, Vol. 113, Núm. 4, pp. 401-406